Psyence Group Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSYG.CN research report →
Companywww.psyence.com
Psyence Group Inc. , a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions.
- CEO
- Jody Aufrichtig
- IPO
- 2021
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $1.88M
- P/E
- -0.12
- P/S
- 0.00
- P/B
- 2.23
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 303.83%
- ROIC
- -417.92%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-400,230 · 99.42%
- EPS
- $-0.04 · 91.75%
- Op Income
- $-5,507,274
- FCF YoY
- 5.79%
Performance & Tape
- 52W High
- $0.38
- 52W Low
- $0.10
- 50D MA
- $0.14
- 200D MA
- $0.17
- Beta
- 1.42
- Avg Volume
- 2.94K
Get TickerSpark's AI analysis on PSYG.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PSYG.CN Coverage
We haven't published any research on PSYG.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSYG.CN Report →